journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/28327971/dpd-testing-must-remain-a-recommended-option-but-not-a-recommended-routine-test
#1
Gerard Milano
No abstract text is available yet for this article.
March 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327908/predicted-vitamin-d-status-and-colon-cancer-recurrence-and-mortality-in-calgb-89803-alliance
#2
M A Fuchs, C Yuan, K Sato, D Niedzwiecki, X Ye, L B Saltz, R J Mayer, R B Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, F Innocenti, R S Warren, M M Bertagnolli, S Ogino, E L Giovannucci, E Horvath, J A Meyerhardt, K Ng
Background: HASH(0x47068a8) Observational studies suggest that higher levels of 25-hydroxyvitamin D 3 (25(OH)D) are associated with a reduced risk of colorectal cancer and improved survival of colorectal cancer patients. However, the influence of vitamin D status on cancer recurrence and survival of patients with stage III colon cancer is unknown. Patients and methods: HASH(0x4147210) We prospectively examined the influence of post-diagnosis predicted plasma 25(OH)D on outcome among 1,016 patients with stage III colon cancer who were enrolled in a National Cancer Institute-sponsored adjuvant therapy trial (CALGB 89803)...
March 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327958/risk-factors-and-a-prognostic-score-for-survival-after-autologous-stem-cell-transplantation-for-relapsed-or-refractory-hodgkin-lymphoma
#3
P J Bröckelmann, H Müller, O Casasnovas, M Hutchings, B von Tresckow, M Jürgens, S J McCall, F Morschhauser, M Fuchs, P Borchmann, C H Moskowitz, A Engert
BACKGROUND: Novel agents are changing the treatment of relapsed or refractory Hodgkin lymphoma (HL). Nevertheless, high-dose chemotherapy and autologous stem-cell transplantation (ASCT) are considered standard of care in eligible patients. To identify patients who could benefit most from novel therapeutic approaches, we investigated a comprehensive set of risk factors for survival after ASCT. METHODS: In this multinational prognostic multivariable modeling study, 23 potential risk factors (RF) were retrospectively evaluated in HL patients from nine prospective trials with multivariable Cox proportional hazards regression analyses (part I)...
March 8, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327968/subjective-and-objective-taste-and-smell-changes-in-cancer
#4
L E Spotten, C A Corish, C M Lorton, P M Ui Dhuibhir, N C O'Donoghue, B O'Connor, T D Walsh
Context: Malnutrition is highly prevalent in cancer patients and an important predictor of morbidity, mortality, treatment response and toxicity. Taste and smell changes (TSCs) are common and may contribute to malnutrition. Research has previously focused on patients receiving chemotherapy (CT) or head and neck radiotherapy (RT). However, TSCs may occur pre-treatment, with other treatment modalities, and in cancer survivors. This review evaluates objective and subjective assessment of taste and smell, discusses the prevalence of TSCs in cancer, and reviews the clinical sequelae of TSCs in cancer patients...
March 7, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327938/targeting-the-fibroblast-growth-factor-receptor-2-in-gastric-cancer-promise-or-pitfall
#5
C Hierro, M Alsina, M Sánchez, V Serra, J Rodon, J Tabernero
Gastric cancer is the third leading cause of death from cancer worldwide. Systemic chemotherapy remains the mainstay therapeutic option for this poor prognosis cancer. Trastuzumab, the epidermal growth factor receptor 2 (ERBB2 or HER2)-antibody, is the only biological agent approved for the molecularly-selected population of HER2-positive gastric cancer patients. Over the last decade, several groups have been working for deepening into the molecular characterization of gastric cancer, shedding some light into the heterogeneity of this tumour...
March 7, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28328007/a-step-towards-the-harmonization-of-clinical-trails-inform-consent-forms
#6
J Remon, C Ferté
No abstract text is available yet for this article.
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327995/adult-weight-gain-and-colorectal-adenomas-a-systematic-review-and-meta-analysis
#7
S Schlesinger, K Aleksandrova, L Abar, A R Vieria, S Vingeliene, E Polemiti, C A T Stevens, D C Greenwood, D S M Chan, D Aune, T Norat
Background: Colorectal adenomas are known as precursors for the majority of colorectal carcinomas. While weight gain during adulthood has been identified as a risk factor for colorectal cancer, the association is less clear for colorectal adenomas. We conducted a systematic review and meta-analysis to quantify the evidence on this association. Methods: : We searched MEDLINE up to September 2016 to identify observational (prospective, cross-sectional and retrospective) studies on weight gain during adulthood and colorectal adenoma occurrence and recurrence...
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327988/efficacy-and-safety-of-nilotinib-in-patients-with-kit-mutated-metastatic-or-inoperable-melanoma-final-results-from-the-global-single-arm-phase-ii-team-trial
#8
J Guo, R D Carvajal, R Dummer, A Hauschild, A Daud, B C Bastian, S N Markovic, P Queirolo, A Arance, C Berking, V Camargo, D Herchenhorn, T M Petrella, D Schadendorf, W Sharfman, A Testori, S Novick, S Hertle, C Nourry, Q Chen, F S Hodi
Background.: The single-arm, phase II Tasigna Efficacy in Advanced Melanoma (TEAM) trial evaluated the KIT-selective tyrosine kinase inhibitor nilotinib in patients with KIT -mutated advanced melanoma without prior KIT inhibitor treatment. Patients and Methods.: Forty-two patients with KIT -mutated advanced melanoma were enrolled and treated with nilotinib 400 mg twice daily. TEAM originally included a comparator arm of dacarbazine (DTIC)-treated patients; the design was amended to a single-arm trial due to an observed low number of KIT -mutated melanomas...
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327975/statistical-controversies-in-cancer-research-using-standardized-effect-size-graphs-to-enhance-interpretability-of-cancer-related-clinical-trials-with-patient-reported-outcomes
#9
M L Bell, M H Fiero, H M Dhillon, V J Bray, J L Vardy
Patient reported outcomes (PROs) are becoming increasingly important in cancer studies, particularly with the emphasis on patient centered outcome research. However, multiple PROs, using different scales, with different directions of favorability are often used within a trial, making interpretation difficult. To enhance interpretability, we propose the use of a standardized effect size graph, which shows all PROs from a study on the same figure, on the same scale. Plotting standardized effects with their 95% confidence intervals on a single graph clearly showing the null value conveys a comprehensive picture of trial results...
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327956/no-pain-no-gain%C3%A2-what-we-can-learn-from-a-trial-reporting-negative-results
#10
A Di Leo, E Risi, L Biganzoli
No abstract text is available yet for this article.
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327928/detecting-mutant-kras-in-liquid-biopsies-a-biomarker-searching-for-a-role
#11
Zoltan Szallasi
No abstract text is available yet for this article.
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327925/abvd-chemotherapy-with-reduced-radiation-therapy-rates-in-children-adolescents-and-young-adults-with-all-stages-of-hodgkin-lymphoma
#12
K C Marr, J M Connors, K J Savage, K J Goddard, R J Deyell
Background: We adopted ABVD chemotherapy with risk-adapted radiation therapy (RT) as first-line therapy for children, adolescents and young adults with Hodgkin lymphoma (HL) in British Columbia (BC) in 2004. Patients and Methods: Patients ≤ 25 years diagnosed from 2004 to 2013 with all stages of HL who received ABVD as initial therapy were included. Results: Among 55 children (age < 18 y) and 154 young adults (18-25 y) there were no significant differences between age groups for sex, histologic subtype, tumour bulk, B symptoms, prognostic risk groups or treatment received...
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327907/a-randomized-open-label-phase-2-study-of-everolimus-in-combination-with-pasireotide-lar-or-everolimus-alone-in-advanced-well-differentiated-progressive-pancreatic-neuroendocrine-tumors-cooperate-2-trial
#13
M H Kulke, P Ruszniewski, E Van Cutsem, C Lombard-Bohas, J W Valle, W W De Herder, M Pavel, E Degtyarev, J C Brase, L Bubuteishvili-Pacaud, M Voi, R Salazar, I Borbath, N Fazio, D Smith, J Capdevila, R P Riechelmann, J C Yao
Background: Several studies have demonstrated the antitumor activity of first-generation somatostatin analogs (SSAs), primarily targeting somatostatin receptor (sstr) subtypes 2 and 5, in neuroendocrine tumors (NET). Pasireotide, a second-generation SSA, targets multiple sstr subtypes. We compared the efficacy and safety of pasireotide plus everolimus to everolimus alone in patients with advanced, well-differentiated, progressive pancreatic NET (pNET). Patients and methods: Patients were randomized 1:1 to receive a combination of everolimus (10 mg/d, orally) and pasireotide long-acting release (LAR; 60 mg/28 d, intramuscularly) or everolimus alone (10 mg/d, orally); stratified by prior SSA use, and baseline serum chromogranin A and neuron-specific enolase...
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327903/successful-mtor-inhibitor-therapy-for-a-metastastic-neuroendocrine-tumour-in-a-patient-with-a-germline-tsc2-mutation
#14
J Schrader, F O Henes, D Perez, S Burdak-Rothkamm, A Stein, J R Izbicki, A W Lohse
No abstract text is available yet for this article.
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327898/adherence-to-capecitabine-in-preoperative-treatment-of-stage-ii-and-iii-rectal-cancer-do-we-need-to-worry
#15
R Font, J A Espinas, L Layos, M Martinez Villacampa, J Capdevila, M Tobeña, A Pisa, C Pericay, C Lezcano, E Fort, I Cardona, N Berga, J Solà, J M Borras
Background: : Preoperative oral capecitabine plus radiotherapy has been progressively adopted in oncology units to provide more convenient care to patients with rectal cancer, but little is known about adherence to this therapy. Patients and methods: : Prospective, multicentre observational study in six hospitals in metropolitan Barcelona (Spain), in patients with stage II and III rectal cancer. Assessment of adherence was based on the medical report in the clinical history, a patient questionnaire and a pill count in the pharmacy service upon finalization of treatment...
March 6, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327982/the-role-of-ar-polyq-tract-in-male-breast-carcinoma-lesson-from-a-sbma-case
#16
Giorgia Querin, Ilaria Martinelli, Cinzia Bertolin, Elena Pegoraro, Maria Pennuto, Gianni Sorarù
No abstract text is available yet for this article.
February 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327919/chemotherapy-in-end-of-life-care
#17
Reino Heikkilä, Stein Kaasa
No abstract text is available yet for this article.
February 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28328000/cdx2-prognostic-value-in-stage-ii-iii-resected-colon-cancer-is-related-to-cms-classification
#18
C Pilati, J Taieb, R Balogoun, L Marisa, A de Reyniès, P Laurent-Puig
Caudal-type homeobox transcription factor 2 (CDX2) is involved in colon cancer (CC) oncogenesis and has been proposed as a prognostic biomarker in patients with stage II or III CC. We analyzed CDX2 expression in a series of 469 CC typed for the new international consensus molecular subtype (CMS) classification, and we confirmed results in a series of 90 CC. Here, we show that lack of CDX2 expression is only present in the mesenchymal subgroup (CMS4) and in MSI-immune tumors (CMS1) and not in CMS2 and CMS3 colon cancer...
February 27, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327984/more-valuable-than-platinum-first-line-pembrolizumab-in-advanced-stage-non-small-cell-lung-cancer
#19
T Zou, M M Awad
No abstract text is available yet for this article.
February 27, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327891/somatic-brca2-bi-allelic-loss-in-the-primary-prostate-cancer-was-associated-to-objective-response-to-parpi-in-a-sporadic-crpc-patient
#20
N Romero-Laorden, E Piñeiro-Yañez, A Gutierrez-Pecharoman, M I Pacheco, E Calvo, F Al-Shahrour, E Castro, D Olmos
No abstract text is available yet for this article.
February 27, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"